3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
2
CNS
1
Conditions
Central Nervous System Neoplasms
20
Brain Neoplasms
12
Medulloblastoma
8
Meningeal Carcinomatosis
6
Rhabdoid Tumor
5
Lymphoma
5
Choroid Plexus Neoplasms
5
Astrocytoma
5
Neuroblastoma
4
Ependymoma
4
Breast Neoplasms
4
Sarcoma
3
Oligodendroglioma
3
Lymphoma, Non-Hodgkin
2
Gliosarcoma
2
Glioblastoma
2
Waldenstrom Macroglobulinemia
1
Spinal Cord Neoplasms
1
Sezary Syndrome
1
Retinoblastoma
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Ototoxicity
1
Osteosarcoma
1
Neurotoxicity Syndromes
1
Neurofibromatosis 1
1
Neurofibroma, Plexiform
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neuroectodermal Tumors, Primitive
1
Interventions
Trastuzumab
2
Radiotherapy
2
Capecitabine
2
tucatinib
1
sapanisertib
1
pertuzumab
1
patritumab deruxtecan
1
paclitaxel-Angiopep-2 conjugate
1
omburtamab I-131
1
fludarabine
1
eribulin
1
avelumab
1
WP 744
1
Temozolomide
1
Spinal Puncture
1
Rituximab
1
Psychiatric Rehabilitation
1
Phlebotomy
1
Methotrexate
1
Cyclophosphamide
1
Amplified Fragment Length Polymorphism Analysis
1
AZD1390
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Meningeal Neoplasms
×
Methotrexate
×
CNS
×
Clear all
NCT03613181
2023-04-24
ANGLeD
Angiochem Inc
Phase 3
Unknown
150 enrolled